Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.

Journal of internal medicine - 1 May 2023

Brun Marthe Kirkesaether, Bjørlykke Kristin Hammersbøen, Viken Marte K, Stenvik Grethe-Elisabeth, Klaasen Rolf A, Gehin Johanna E, Warren David John, Sexton Joseph, Sandanger Øystein, Kvien Tore K, Mørk Cato, Haavardsholm Espen A, Jahnsen Jørgen, Goll Guro Løvik, Lie Benedicte A, Bolstad Nils, Jørgensen Kristin Kaasen, Syversen Silje Watterdal

Abstract excerpt

BACKGROUND: Immunogenicity to tumour necrosis factor inhibitors is a significant clinical problem leading to treatment failure and adverse events. The study aimed to assess human leukocyte antigen (HLA) associations with anti-drug antibody (ADAb) formation to infliximab. METHODS: Immune-mediated inflammatory disease patients on infliximab therapy (n = 612) were included. Neutralising ADAb were assessed with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antibody Formation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Celiac Disease

Share to Genetic Predisposition to Disease

Share to Haplotypes

Share to HLA-DQ alpha-Chains

Share to Infliximab

Source

Identifiers

PMID: 36843323
DOI: 10.1111/joim.13616

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.PMID 36843323Read ↗

HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapySemantic proximity Read ↗

Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and InfliximabSemantic proximity Read ↗

Identification of HLA-DRB1 association to adalimumab immunogenicity.Semantic proximity Read ↗

HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.Semantic proximity Read ↗

Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use.Semantic proximity Read ↗

Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

HLA Class II Alleles Are Associated With Anti-Drug Antibodies in Ulcerative Colitis Patients Treated With Etrolizumab.Semantic proximity Read ↗

Validation of a rapid HLA-DQA1*05 pharmacogenomics assay to identify at-risk resistance to anti-tumor necrosis factor therapy among patients with inflammatory bowel disease.Semantic proximity Read ↗

HLA Class II Alleles are associated with Anti-Drug Antibodies in Ulcerative Colitis Patients Treated with EtrolizumabSemantic proximity Read ↗

Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD PatientsSemantic proximity Read ↗

HLA-DQA1*05 Carriage is Associated with treatment failure and the induction of anti-IFX antibodies in IBD patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.